Composition, form of production and packaging
? Tablets chewing orange in color with a small amount of white impregnations, round, smooth, with a facet and a risk.
ubedecarenone (coenzyme Q10) 50 mg
Excipients: macrogol 6000 - 500.1 mg, isomalt - 80.7 mg, sodium carmellose - 35 mg, ascorbic acid - 30 mg, sodium stearyl fumarate - 3.5 mg, aspartame - 0.7 mg.
10 pieces. - packings of cellular contour (1) - packs cardboard.
10 pieces. - packings cellular planimetric (2) - packs cardboard.
10 pieces. - packings cellular planimetric (3) - packs cardboard.
10 pieces. - packings cellular planimetric (4) - packs cardboard.
10 pieces. - packings cellular planimetric (5) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2015.
Cardiotonic preparation of non-glycosidic structure. Ubidekarenone is a natural substance, which is a vitamin-like coenzyme. Ubidekarenone (coenzyme Q10, ubiquinone) is an endogenous substrate, participates in the transfer of electrons in the transport chain of oxidation-reduction processes, during energy metabolism, in the reaction of oxidative phosphorylation in the respiratory chain of mitochondria of cells. Participates in the processes of cellular respiration, increasing the synthesis of ATP. Has a clinically significant antioxidant effect. Ubidekarenon protects the lipids of cell membranes from peroxidation, reduces the area of вЂ‹вЂ‹myocardial damage under conditions of ischemia and reperfusion. Ubidekarenon prevents the prolongation of the QT-interval, improves the tolerance of exercise.
Due to endogenous synthesis 100% satisfaction of the body's need for coenzyme Q10 occurs only up to the age of 20 years. The content of coenzyme Q10 decreases in elderly patients, as well as in various diseases, both in adults and in children.
Clinical studies of the pharmacokinetics of the drug have not been conducted.
Experimental studies in animals have shown that after ingestion the drug is rapidly absorbed, T max in plasma is achieved 1 h after administration. Bioavailability of the drug is 20%.
T 1/2 is 2 hours. The drug is excreted in the urine in the unchanged form and in the form of metabolites.
- in the complex therapy of IHD (including myocardial infarction - the period of restorative therapy), chronic heart failure, arterial hypertension;
- for the prevention and replacement of coenzyme Q10 deficiency;
- to improve the adaptation to increased physical exertion in athletes.
As part of complex therapy in the treatment of IHD and chronic heart failure, 150 mg (3 tab.) / Day in 3 divided doses are used. Tablets should be chewed.
In the complex therapy of hypertension, in order to make up for the deficiency of coenzyme Q10 and improve adaptation to increased physical exertion, athletes are used in a dose of 50-100 mg (1-2 tablets) / day. Tablets should be chewed.
The duration of the course of taking the drug is 1-3 months.
From the digestive system: dyspeptic phenomena (heartburn, epigastric pain, nausea, vomiting, diarrhea) are possible.
From the side of the cardiovascular system: a decrease in blood pressure, tachycardia is possible.
Allergic reactions: skin redness, itching, swelling of the nasal mucosa, allergic conjunctivitis are possible.
- severe arterial hypotension (blood pressure less than 90/60 mm Hg);
- severe bradycardia (heart rate less than 50 beats per minute);
- acute glomerulonephritis;
- Stomach ulcer and duodenal ulcer in the phase of exacerbation;
- the period of lactation (breastfeeding);
- Hypersensitivity to the components of the drug.
PREGNANCY AND LACTATION
The drug is not recommended for use during pregnancy and lactation (breast-feeding), because Strictly controlled clinical trials of drug safety in pregnant and lactating women were not conducted.
APPLICATION FOR FUNCTIONS OF THE LIVER
Contraindicated in acute glomerulonephritis.
APPLICATION IN ELDERLY PATIENTS
The application is possible according to the dosing regimen.
With caution should apply the drug with arterial hypotension.
Impact on the ability to drive vehicles and manage mechanisms
There is no evidence of adverse effects of the drug on the ability to drive vehicles and mechanisms.
Cases of drug overdose Valeocor-Q10 В® are not known.
Valeocor-Q10 В® potentiates the pharmacological effects of cardiotonic, antihypertensive, antianginal agents.
Simultaneous use of lipid-lowering drugs (inhibitors of HMG-CoA reductase, fibrates), beta-blockers (atenolol, metoprolol, propranolol), warfarin, tricyclic antidepressants can lead to a decrease in the concentration of ubidecarenone in the blood plasma.
TERMS OF RELEASE FROM PHARMACY
The drug is approved for use as a means of OTC.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of reach of children, dry, protected from light at a temperature of no higher than 25 В° C. Shelf life - 2 years. Do not use after the time specified on the package.